These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1309147)

  • 21. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Susceptibility to norfloxacin of some bacterial strains causing urinary infections].
    Tuchiluş C; Poiată A; Bădicuţ I; Buiuc D
    Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):383-6. PubMed ID: 16607805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance pattern of enterobacteriaceae isolates from urinary tract infections to selected quinolones in Yaoundé.
    Lyonga EE; Toukam M; Nkenfou C; Gonsu HK; Assoumou MC; Mesembe MT; Eyoh AB; Ikomey GM; Ndze VN; Koulla-Shiro S
    Pan Afr Med J; 2015; 21():105. PubMed ID: 26327943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to oral antibiotics in urinary coliform strains isolated between 2000 and 2008 in Sønderborg area, Denmark.
    Cybulski Z; Kjaeldgaard P
    Int J Antimicrob Agents; 2010 May; 35(5):516-7. PubMed ID: 20202798
    [No Abstract]   [Full Text] [Related]  

  • 25. [Study of nalidixic acid activity on 3186 strains of Gram negative bacilli. Application to the treatment of urinary infections].
    Chamfeuil R; Curcier H
    Presse Med (1893); 1969 Nov; 77(48):1763-4. PubMed ID: 4903534
    [No Abstract]   [Full Text] [Related]  

  • 26. [In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
    Soussy CJ; Leclercq R; Deforges L; Duval J
    Pathol Biol (Paris); 1989 May; 37(5):364-9. PubMed ID: 2506511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Therapy of urinary tract infections: striking Gram-negative germs. Changes in the bacterial spectrum and resistance in a group of patients over an 18-year period].
    Gussmann S
    Fortschr Med; 1983 Sep; 101(36):1626-9. PubMed ID: 6629294
    [No Abstract]   [Full Text] [Related]  

  • 28. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L; Devos J; Romond C; Bryskier A
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nalidixic acid.
    Bailey RR
    JAMA; 1977 Jun; 237(25):2720. PubMed ID: 577224
    [No Abstract]   [Full Text] [Related]  

  • 30. Antibiotic resistance in adult female patients hospitalized for acute pyelonephritis: rates and predicting factors.
    Etienne M; Van Elslande H; Choplin-Renard J; Pestel-Caron M; Caron F
    Med Mal Infect; 2014 May; 44(5):217-22. PubMed ID: 24787633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to nalidixic acid. A misconception due to underdosage.
    Stamey TA; Bragonje J
    JAMA; 1976 Oct; 236(16):1857-60. PubMed ID: 989536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Sensitivity of clinical bacterial strains to ofloxacin].
    Borowski J; Jakubicz P
    Pol Tyg Lek; 1990 Sep 3-10; 45(36-37):745-7. PubMed ID: 2128121
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comparison of the antibacterial effects of ofloxacin, oxolinic acid and nalidixic acid].
    Langsádl L; Menkyna R; Golier J; Silan L
    Cesk Epidemiol Mikrobiol Imunol; 1988 Sep; 37(5):297-308. PubMed ID: 3197127
    [No Abstract]   [Full Text] [Related]  

  • 34. Transferable drug resistance (R-factor) among the enterobacteriaceae in urinary tract infections: a study at an urban hospital in Bangladesh.
    Chowdhury MA; Rahman KM; Miah MR; Haq JA
    J Trop Med Hyg; 1994 Jun; 97(3):161-6. PubMed ID: 8007056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance patterns of Enterobacteriaceae in urines are similar in symptomatic and asymptomatic patients.
    Romero Palacios A; Al Dhufairi F; Ellis C; Smyth D; Mieusement LMD; McGeer A; Mertz D
    J Hosp Infect; 2018 Aug; 99(4):419-421. PubMed ID: 29432819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Urinary infections by enterobacteriaceae resistent to antimicrobial agents].
    Ales Reinlein JM; Vela Navarrete R; Fernández Puentes MC; Silva M
    Rev Clin Esp; 1973 Aug; 130(4):295-300. PubMed ID: 4755593
    [No Abstract]   [Full Text] [Related]  

  • 37. [The effect of drug preparations on the expression of the persistence properties of uropathogenic strains of enterobacteria].
    Chelpachenko OE; Zykova LS
    Zh Mikrobiol Epidemiol Immunobiol; 1996; (3):84-6. PubMed ID: 8771740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of ESBL-producing enterobacteria associated to community-acquired monomicrobial urinary tract infections and antimicrobial susceptibility trends over a 9-year period.
    Dias VC; da Silva VL; Firmo Ede O; Bastos LQ; Bastos AN; Bastos RV; Diniz CG
    J Chemother; 2012 Jun; 24(3):178-81. PubMed ID: 22759764
    [No Abstract]   [Full Text] [Related]  

  • 39. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In vivo bactericidal effect of ciprofloxacin, ofloxacin and pefloxacin against Staphylococcus aureus].
    Tronel H; Voiriot P; Weber M; Dopff C; Dewachter P; Phelisse F; Dureux JB
    Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):578-81. PubMed ID: 2797882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.